Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centersCARY, N.C. and…
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc.,…
Isomorphic Labs secures $2.1 Billion funding to scale its AI drug design engine
Isomorphic Labs will use the funding to power its world-leading AI drug…
Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary
Former Edgewise and Merck leader brings more than 15 years’ experience to…
Cellenkos Announces FDA Clearance of Investigational New Drug (IND) Application for Phase 1b/ 2a Trial of CK0802 in Steroid-Refractory Graft-versus-Host Disease (GVHD)
Multicenter, open-label study will evaluate the safety and preliminary efficacy of CK0802,…
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
ANDERNACH, Germany, April 29, 2026 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"),…
ArkBio Completed Dosing of First Cohort in Australian Phase I Trial of Antiviral Drug-Fc Conjugate Drug AK0406
SHANGHAI, April 10, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
API Innovation Center Highlights Fragility in U.S. Drug Supply Chain in New White Paper
ST. LOUIS, March 10, 2026 (GLOBE NEWSWIRE) -- The API Innovation Center (APIIC),…
U.S. Food and Drug Administration (FDA) Accepts Tevas New Drug Application (NDA) for Olanzapine Extended-Release Injectable Suspension (TEV-‘749) for the Once-Monthly Treatment of Schizophrenia in Adults
Olanzapine long-acting injectable (LAI) suspension (TEV-'749) has the potential to offer the…
Harness Therapeutics Nominates HRN001, a First-in-Class Drug Candidate for Huntingtons Disease and Establishes Clinical Advisory Board
HRN001 is a potent and specific antisense oligonucleotide designed to drive controlled…
